New Regulatory Regime For 8 Medical Items Under Drugs And Cosmetics Act

New Delhi : Adopting a proactive and sensitive approach to address the needs of the Indian Industry, the Union Ministry of Health & Family Welfare has taken a significant decision for ensuring continued access of eight regulated medical devices today.

The Ministry had earlier notified the following medical items to be regulated under the Drugs and Cosmetics Act which was to come into effect from 1st April, 2021 (as per S.O. 775(E) dated 08th February, 2019 under Medical Devices Rules 2017):

  1. All Implantable Medical Devices;
  2. CT scan equipment;
  3. MRI equipment;
  4. Defibrillators;
  5. PET Equipment;
  6. Dialysis Machine;
  7. X-Ray Machine; and
  8. Bone marrow cell separator.

Accordingly, as per the said order the importers/manufacturers are required to take import/manufacturing licence from Central Licencing Authority or State Licencing Authority, as the case may be, for import/manufacture of above devices, w.e.f. 1st April, 2021.

In order to ensure  supply chain continuity and access to these Medical Devices, while implementing  smooth transition into the new regulatory regime, Union Ministry of Health and Family Welfare has now decided that in case an existing importer/manufacturer who is already importing /manufacturing any of these devices, has submitted application to Central Licencing Authority or State Licencing Authority, as the case may be, for grant of import /manufacturing licence in respect of the said device(s) under the provisions of MDR, 2017, the said application shall be deemed valid and the importer/manufacturer can continue to import /manufacture the said device(s) up to 6 months from issue of this order or till the time, the Central Licencing Authority or State Licencing Authority, as the case may be, takes a decision on the said application, whichever is earlier. Order in this regard has been issued by Drugs Controller General (India) on 18th April 2021 through CDSCO website.

[pdf-embedder url=”https://medicarepharmabusiness.com/wp-content/uploads/2021/04/MDnotice18-190421073032.pdf”]

  • Related Posts

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    The Konkan division of Maharashtra ANTF raided three different locations in Bengaluru, during which the drug manufacturing units were busted. BENGALURU:  While the state government is aiming to make Karnataka…

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    New Delhi: A pharma group has sought extension for those production units that have already submitted upgradation plans and can demonstrate execution progress, even as the drug regulatory authority seems…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    Maha cops bust three factories, seize drugs worth Rs 56 crore in Bengaluru

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    ‘Drug companies in upgrade mode need more time for GMP compliance’: IDMA

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    Obesity treatment drugs to be new growth engine for pharma industry: Sun Pharma

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    National Pharmaceutical Pricing Authority fixes retail price of 37 new drugs

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Massive Drug Bust in Bijnor: CBN Seizes Over 6.5 Lakh Tablets

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US

    Sun Pharma unit recalls 17,000-plus bottles of antifungal shampoo in US